• Youssef Ben Bouazza, Ibrahim Chiairi, Ouiam El Kharbouchi, Lesley De Backer, Greetje Vanhoutte, Annelies Janssens, and Jan P Van Meerbeeck.
• Faculty of Medicine and Health Care, Antwerp University, Universiteitsplein 1, 2610 Antwerpen, Belgium; Rietbeemd 36, 4907 ED Oosterhout, The Netherlands. Electronic address: youssef.benbouazza@student.uantwerpen.be.
• Lung Cancer. 2017 Nov 1; 113: 140-151.

AbstractLung cancer is often associated with a poor quality of life, as reflected by patient-reported outcome measures (PROMs). The aim of this paper is to describe and compare the PROMs that are available. In this manuscript, we review the impact of PROMs on the management of lung cancer. Quality of the study and risk of bias were assessed using the appraisal tools recommended by the Dutch Cochrane Center. Out of 51 studies included in this review, ten instruments were identified and categorized as either generic, cancer- or lung cancer-specific. PROMs are primarily applied in scientific research to compare the therapy outcomes and in drug development to support labeling claims. The interest for the routine use of PROMs in daily practice is growing, which has positive effects on the communication with the patient, mutual decision making and the monitoring and managing of the patient. Besides that, PROMs have an independent prognostic value for survival in lung cancer and economic evaluations can be conducted using their results. Electronic platforms simplify the implementation of PROMs in the daily clinic. The EORTC QLQ-C30 and its lung cancer-specific module QLQ-LC13 are the most frequently used instruments in lung cancer patients. PROMs have the potential to improve the quality of care with a proper implementation in the routine practice. PROMS are needed to value and understand the experience of the patient.Copyright © 2017. Published by Elsevier B.V.

19 keywords...

hide…